Reviews/Targeted Therapy Prostate Cancer/Radium-223 overall survival in bone-only metastatic castration-resistant prostate cancer
Bone · PC-BONE-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
A large, well-designed randomised trial (ALSYMPCA) tested radium-223 against placebo in men with castration-resistant prostate cancer that had spread to bone but not to internal organs. It found people lived longer on radium-223, with the exact effect size the claim names appearing in the records the panel read [8][11], alongside identical median survival figures of 14.0 versus 11.2 months. Several real-world studies of radium-223 report survival in a similar range [2][12][17], which fits the picture but cannot by themselves prove patients did better than they would have on placebo. The main limitation the panel flagged is that all the comparative evidence comes from this single trial, and the corpus holds only a conference abstract [11] and a regulatory summary [8] of it rather than the full published paper. The population, direction and size of the effect all line up precisely with what the claim states.
The corpus carries the ALSYMPCA primary result in two places reporting the same trial: a regulatory approval summary giving HR 0.70, 95% CI 0.55-0.88, P=0.0019, median OS 14.0 vs 11.2 months [8], and a conference abstract giving HR 0.695, 95% CI 0.552-0.875, P=0.00185, median OS 14.0 vs 11.2 months in 922 randomised patients [11]. Both specify the claimed population: castration-resistant prostate cancer with bone metastases and no known visceral disease [8][11]. Single-arm real-world and expanded-access cohorts report median overall survival of 16.27 months [2], 17 months [12] and 23.0 months [17], consistent with the survival magnitude but carrying no placebo comparator. An ALSYMPCA exploratory subgroup analysis [14] and an early-access cohort [16] add supportive context without providing an independent comparative estimate. The contested point: The division is about evidential independence rather than the finding itself: the comparative survival benefit comes entirely from one trial, reported in the corpus only through a conference abstract [11] and an FDA summary [8], which are two views of the same dataset rather than independent confirmation. The reported HR is also drawn from a prespecified interim analysis [8], and every corroborating cohort [2][12][16][17][18] is single-arm and so cannot establish the comparative effect.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The entire comparative OS/HR rests on a single trial (ALSYMPCA); [8] and [11] report the same dataset via an FDA summary and a conference abstract, so they are not independent corroboration of the effect.
The corpus contains no full peer-reviewed primary publication of ALSYMPCA, only a conference abstract [11] and a regulatory narrative [8]; [1], the 'updated analysis,' has placeholder text with no reported results.
Where it remains uncertain. All comparative evidence rests on this single trial, available in the corpus only as a conference abstract [11] and a regulatory summary [8], with the HR drawn from a prespecified interim analysis [8].
Aleatory
The HR 0.70 is reported at a prespecified interim analysis [8], so the estimate reflects accumulated events at that cut rather than a final mature readout.
Epistemic
The comparative overall-survival benefit derives entirely from ALSYMPCA; [8] and [11] report the same dataset, so the corpus holds no independent comparative confirmation.
Inferential
Cohorts [2][12][16][17][18] report absolute median survival without a placebo comparator, so reading them as confirming the comparative HR would be an inferential overreach.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independently reported regulatory confirmation of the exact HR 0.70 and median OS values in the claim
“approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease”
Panel auditInternal validity: high · scope of inference: Overall survival of radium-223 vs placebo in CRPC patients with symptomatic bone metastases and no known visceral metastatic disease.Key limitations: secondary regulatory summary not primary report · no sample size stated in abstract · interim analysis
Primary ALSYMPCA RCT result establishing the significant comparative OS benefit (HR 0.695 ≈ 0.70) vs placebo
“Eligible pts had progressive, symptomatic CRPC with ≥ 2 bone mets on scintigraphy and no known visceral mets”
Panel auditInternal validity: high · scope of inference: Overall survival of radium-223 vs placebo in progressive symptomatic CRPC with at least 2 bone metastases and no known visceral metastases.Key limitations: conference abstract · interim analysis · symptomatic population
Independent single-arm real-world cohort corroborating survival magnitude (no comparator)
“Median overall survival was 17 months, with 134/184 (73%) patients censored because of short follow-up due to radium-223 approval.”
Panel auditInternal validity: low · scope of inference: Safety and OS of radium-223 in US expanded-access symptomatic mCRPC patients, including concurrent abiraterone or enzalutamide.Key limitations: no comparator arm · 73% censored · post hoc analyses
The abstract text is an ASCO placeholder stating the full text will be released later; it contains no result, effect size or population detail.
Panel auditInternal validity: not assessable from abstract · scope of inference: None determinable from this abstract.Key limitations: placeholder abstract · no data reported
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The exact HR 0.70 and matching population appear verbatim in the pivotal trial's primary data, with consistent corroboration, but evidential independence is limited to a single trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent comparative trial. The HR rests on a single RCT reported twice in the corpus, limiting evidential independence. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second randomised placebo- or active-controlled trial of radium-223 in the same population reporting overall survival.
Open question: Does the HR 0.70 overall-survival benefit hold at ALSYMPCA's final mature analysis? Why it is still open: The corpus reports the effect only at a prespecified interim analysis [8], and the 'updated analysis' entry [1] carries no results.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19